Patent 8716327 was granted and assigned to Genzyme on May, 2014 by the United States Patent and Trademark Office.
The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.